Current status and future directions in the pharmacotherapy of epilepsy.
about
Lamotrigine add-on for drug-resistant partial epilepsyMechanisms of seizure propagation in 2-dimensional centre-surround recurrent networksModern antiepileptic drug development has failed to deliver: ways out of the current dilemma.Focused ultrasound-mediated suppression of chemically-induced acute epileptic EEG activity.Eliminating Absence Seizures through the Deep Brain Stimulation to Thalamus Reticular Nucleus.Functional variant in complement C3 gene promoter and genetic susceptibility to temporal lobe epilepsy and febrile seizuresAnticonvulsant effect of exogenous β-hydroxybutyrate on kainic acid-induced epilepsy.Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.Animal models of limbic epilepsies: what can they tell us?Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.Antiepileptic drugs in neuroprotection.Anticonvulsant and related neuropharmacological effects of the whole plant extract of Synedrella nodiflora (L.) Gaertn (Asteraceae)Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.Epileptogenesis and rational therapeutic strategies.Channelopathies in idiopathic epilepsy.Clinical characteristics of patients with benign nonlesional temporal lobe epilepsy.Antiepileptic effects of silk-polymer based adenosine release in kindled rats.Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective.Mechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery.Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.Transplantation of bone marrow mononuclear cells modulates hippocampal expression of growth factors in chronically epileptic animals.Pu-erh Tea Protects the Nervous System by Inhibiting the Expression of Metabotropic Glutamate Receptor 5.Anticonvulsant enaminones depress excitatory synaptic transmission in the rat brain by enhancing extracellular GABA levels.Modulation of c-Fos and BDNF protein expression in pentylenetetrazole-kindled mice following the treatment with novel antiepileptic compound HHL-6.Novel actions of oxazolidinones: in vitro screening of a triazolyloxazolidinone for anticonvulsant activity.Kindling-induced overexpression of Homer 1A and its functional implications for epileptogenesis.Furosemide and mannitol suppression of epileptic activity in the human brain.Homocysteine thiolactone-induced seizures in adult rats are aggravated by inhibition of inducible nitric oxide synthase.Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER).The Mechanism of Anti-Epileptogenesis by Levetiracetam Treatment is Similar to the Spontaneous Recovery of Idiopathic Generalized Epilepsy during Adolescence.Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats.Current Study of the Mechanism of Action of the Potential Anti-Epileptic Agent Q808.Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs.Synthesis and pharmacological evaluation of novel 1'-[2-(difluoromethoxy)benzyl]-2'H,5'H-spiro[8-azabicyclo[3.2.1]octane-3,4'-imidazolidine]-2',5'-diones and their derivatives.Effects of Nigella sativa on apoptosis and GABAA receptor density in cerebral cortical and hippocampal neurons in pentylenetetrazol induced kindling in rats.Anticonvulsant, but not antiepileptic, action of valproate on audiogenic seizures in metaphit-treated rats.Decreased Efficacy of GABAA-receptor modulation by midazolam in the kainate model of temporal lobe epilepsy.Preclinical to Clinical Translation of Studies of Transcranial Direct-Current Stimulation in the Treatment of Epilepsy: A Systematic Review.Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment.
P2860
Q26471446-DF2F28E1-CB5A-4193-85F3-DBBA1336CC81Q27309403-B6A4CD59-BFE7-4C01-AFFB-E5BD46906F2DQ27693823-83742D32-A28C-4326-80AE-3BD77565C59DQ30476237-71BC2C62-392C-4320-ABBC-0105B29AC629Q33575859-EB685916-6DBA-477E-A55D-67C4EBAD350BQ33700488-AF0DABA7-8C12-449E-AD72-BE9D7D7CF0F7Q33847306-8D2AB0C8-0D2A-49A9-B940-F1BBD5F202AEQ33985133-83E2DC6A-D360-4272-BAC3-5529A481A8D2Q34458158-71D6F5EE-4CCE-4A61-BD2F-801ADAF0F810Q34604307-719B44AD-D320-43B0-9922-94AA15A852B4Q34788228-47E6A1D6-324E-4D21-9661-3C0C9756F31EQ35753392-45E8F57B-28DC-4A8B-8955-BBCB0E6E4973Q35926676-E6F10707-CE9C-4586-8FAB-6F6E81089CDAQ36157234-ADC37B7E-1552-473E-8725-1167D1BEF96AQ36379406-811828CE-4AA2-4D9E-8C7F-63E74A8FC01FQ36774738-17BECB59-BD7A-487F-BD68-072E62677ACCQ37142983-1E2EC32E-2300-40F6-8910-D3A1824B0CEEQ37310106-875F2BE7-2444-4A5F-9A00-202F6FA5627BQ37900131-A18CC03D-BFF8-4F83-9AA2-147E73894FDAQ38088316-C7F1D663-8F55-44A2-869F-9894D247B5D5Q41139588-FF670D4A-B54F-4C4B-9672-698825481787Q41488975-039CAD10-3A39-4CF4-BD3D-A6CE28FDD0D5Q41829077-1C2196BF-69DA-450A-9816-74E1B3AA83F3Q41830219-D966DE6A-A8F1-4819-9B18-3C7772D9CCB2Q41957846-2391B128-8AAF-4B81-93FF-F9DBC4CBC84DQ42759797-D6B713CC-9E39-4E22-B15F-BCF696E3FE4EQ44243000-3A2FC1C3-2421-44FA-927E-624A5558EE5CQ45281044-BB308F4E-7BCD-4C1F-8E15-DF0D77755493Q46164698-EB92094A-8965-41A3-A0C6-45D3BEE34C95Q46629490-D1129130-CE2D-4CE3-92BB-31EDA2F10969Q47146025-75B36F97-BF3F-4842-A9DE-0E8C3F74E46FQ47585978-5B64B301-6B91-4ED5-8FE5-974993A019C8Q47949685-222B0ED2-5AD2-4BA6-9EF8-01C0E3F603A2Q48259294-69D5B426-87A1-4796-AE9E-1DAE29492FC1Q48367385-82B0E372-F3EF-4FFC-9452-02D75A479ED0Q48428580-FA807A60-40E9-4C85-A092-09D75955D785Q48459209-5E3741B8-36EA-45C8-867F-D5AB03F137C8Q48605589-FCF30867-A072-481E-8F6F-A6DC5DC75391Q52603666-273BD2C4-91F0-4D4F-AAFC-11FC94216E2BQ53859498-83334256-F6E5-433C-B3E7-424BEEA93314
P2860
Current status and future directions in the pharmacotherapy of epilepsy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Current status and future directions in the pharmacotherapy of epilepsy.
@ast
Current status and future directions in the pharmacotherapy of epilepsy.
@en
Current status and future directions in the pharmacotherapy of epilepsy.
@nl
type
label
Current status and future directions in the pharmacotherapy of epilepsy.
@ast
Current status and future directions in the pharmacotherapy of epilepsy.
@en
Current status and future directions in the pharmacotherapy of epilepsy.
@nl
prefLabel
Current status and future directions in the pharmacotherapy of epilepsy.
@ast
Current status and future directions in the pharmacotherapy of epilepsy.
@en
Current status and future directions in the pharmacotherapy of epilepsy.
@nl
P1476
Current status and future directions in the pharmacotherapy of epilepsy.
@en
P2093
Wolfgang Löscher
P304
P356
10.1016/S0165-6147(00)01974-X
P577
2002-03-01T00:00:00Z